A concise chemical synthesis of a series of structurallydefined heparin-like oligosaccharides is described. This work provides an efficient entry to octa-, deca-, and 10 dodecasaccharides, including the first synthesis of (GlcNS6S-IdoA2S) 5 and (GlcNS6S-IdoA2S) 6 . Evaluation of the in vitro activity of these species against FGF2-and VEGF 165dependent endothelial cell proliferation and migration establishes that octa-and decasaccharides are more potent in 15 targeting FGF2-induced effects, where cell migration is affected more significantly than proliferation. These structure-activity relationships exemplify the significance of 6-O-sulfation in regulating the activity of angiogenic growth factors. 20 Heparin and heparan sulphate (H/HS) are highly-charged, ubiquitous, naturally-occurring glycosaminoglycans (GAGs) which are involved in regulating a wide range of biologically important cellular signalling events that control a variety of 25 70 cytokine activity by HS and provides important structure-activity information, which will prove insightful in the future design and development of new anti-angiogenic synthetic HS agents. 75 
biological functions, including angiogenesis. 1 Amongst these, angiogenic signalling pathways that control angiogenesis are regulated by pro-angiogenic and anti-angiogenic cytokines, many of which depend on H/HS for their biological activity.
Fibroblast Growth Factor 2 (FGF2) and Vascular Endothelial 30 Growth Factor 165 (VEGF 165 ) are potent pro-angiogenic cytokines which require HS to bind and activate their respective receptors. 2a,b We have previously demonstrated the relevance of the H/HS-cytokine axis to human cancer, 2c-h through investigation of size fractionated heparin-like oligosaccharides as putative 35 competitive inhibitors of H/HS function in vitro 2a,i and in vivo, 2j demonstrating the potency of octa-and deca-saccharides. There is considerable interest in developing synthetic, structurally-defined H/HS sequences as tools to further probe these angiogenic signalling pathways and for other structural 40 interaction studies. Efficient synthetic routes, as well as access to a diversity of functionality, are essential to provide such agents to interrogate a range of biological targets and also with relation to potentially developing new anti-angiogenic therapies. 3 A number of reports concerning the construction of various 45 H/HS architectures are known and address variation of sequence length and sulfation pattern. 4 The majority of these target the (IS) n repeating sequence, 5 with disaccharide-based strategies typically introducing the S-I anomeric linkage or employing iditol-based rather than iduronate donors. Noteworthy also are 50 recent approaches utilising chemoenzymatic methodologies 6 and efforts towards sequences containing mixed (GS/IS) oligomers. 7 Herein we report the first example of the total synthesis of structurally defined (SI) 5 deca-and (SI) 6 dodecasaccharides 27 and 28 ( Figure 1 ) and in vitro evaluation of their ability to 55 modulate FGF2-and VEGF 165 -dependent endothelial cell functions. 
60
The synthesis of these novel deca-and dodecassaccharides compliments the synthesis of the alternative dodecasaccharide sequence (IS) 6 reported by the Bonnaffé group 1d and an (SI) 4 octasaccharide, similar to 26, reported by Martin-Lomas' group. 4d Furthermore, our optimized approach provides rapid iterative 65 access to multi-hundred mg quantities of octasaccharide 15, scalability which is pivotal to further elongations up to and including novel dodecasaccharide 19. The work was underpinned by developing a reliable 2+(2) n disaccharide iteration strategy for oligosaccharide chain elongation using stable thioglycoside 70 iduronate donors, illustrated generically in Figure 2 . Iterative homologation from disaccharide level through to 8-, 10-and 12-mers, followed by deprotections/sulfations to access heparin-This efficient synthesis utilizes only two disaccharide building blocks, 9 and 10, proceeding with very effective control over introduction of the pivotal α-1,4, I-S linking stereochemistry with yields reliably averaging 75% for each successive round of (2step) homologation. 5 To provide the requisite reducing-end cap monosaccharide 6 required to prepare the key initial disaccharide 9, we further exploited our diastereomerically pure cyanohydrin derivative 1. 8 We have previously shown the conversion of 1 into thioglycoside iduronates of type 2 (Scheme 1) and their use as effective 10 glycosyl acceptors to access H/HS disaccharide building blocks (including donor 10). Whilst that elaboration relied on an initial conversion of 1 via intermediary L-iduronamide derivatives, here we report that alternative Pinner type conditions convert 1 directly into methyl glycosides of the iduronate methyl ester in 15 77% yield. Whilst this afforded the expected mixture of pyranoside and furanoside diols, subsequent acetylation furnished 3 and 4 in high yield (93%) and allowed ready separation of these pyranoside and furanoside isomers, thus facilitating provision of 5 through deacetylation of 3 in 89% yield (Scheme 1). Following regioselective C-2 acylation of 5 using stannaneacetal chemistry, 4g chromatographic separation afforded α-6 and β-6 in 70% overall yield. This route provides a new and scalable entry (13.1 g of 5 prepared) into iduronate acceptors of this type, 9 35 utilizing simple hydrolysis and acylation processes and is available in only four steps from cyanohydrin 1 (which we have shown to be available on Kg scale) and only eight steps (34% overall yield) from commercially available diacetone-D-glucose.
Glycosylation of α-6 was then effected using glucosamine-40 derived trichloroacetimidate donor 7 8a,c under standard conditions, giving novel disaccharide 8 in 78% yield (Scheme 2). The α-selectivity of this glycosylation was confirmed as >95% by 1 H NMR analysis (GlcN J 1,2 = 3.7 Hz for 8). Facile removal of the 4-O-TCA group from 8 using mildly 55 basic conditions provided acceptor 9 in 95% yield. This novel disaccharide then served as the pivotal reducing terminal for iteration towards longer oligosaccharide sequences.
With effective access to 9, our iterative 2+(2) n process constituted removal of the glucosamine-4-O-TCA from each new 60 intermediate oligosaccharide followed by coupling with disaccharide donor unit 10 in each iterative cycle so that the synthesis only needed to address the introduction of I-S linkages.
Hence, coupling of 9 with 10 furnished tetrasaccharide 11 in 66% yield (Scheme 3) and removal of the 4-O-TCA protecting 65 group from 11 then gave 12 in excellent yield (91%), ready for further elongation. Continuation of this iterative glycosylation sequence was then successfully applied through two further cycles, homologating tetrasaccharide 12 into octasaccharide 15 (Scheme 3) with good yields and selectivity for each 70 glycosylation step and consistently over 85% yield for 4-O-TCA deprotection. Our multi-gram access to the disaccharide building blocks, combined with this efficient homologation sequence, meant this methodology was effective for batch synthesis of >800mg quantities of octasaccharide 15. This provides an 75 impressive 5 step route from disaccharide 9 to protected octasaccharide 15 in 19% overall yield and compares well to previous work delivering the closest related octasaccharide in 12% yield (7 steps Octasaccharide 15 was then further elaborated to afford novel deca and dodecasaccharides 17 and 19 using the same iteration process (Scheme 4), with acceptor octasaccharide 16 elaborated into the novel dodecasaccharide 19 in 40% overall yield.
This oligosaccharide iteration proved extremely reliable and each round of glycosylation/deprotection could be completed in under 24 h. This demonstrates an efficient capability to more readily access a range of heparin-like oligosaccharides on a scale 5 not accessible by other means and with the potential for incorporation of disaccharides with specific sulphation patterns.
The fully protected octa-, deca-and dodecasaccharides 15, 17 and 19 were then elaborated into the target species via a four-step deprotection and N/O-sulfation sequence (Scheme 5). (for 21 and 22) . 35 Utilisation of microwave irradiation for this step saw a significant reduction in reaction time (1.5 h vs 18h) and better overall yields. O-sulfation was followed by hydrogenation to remove the benzyl protecting groups and reduce the azides to furnish 23-25 in good yields over the two steps. A final step N-sulfation of the 40 glucosamine NH 2 residues was effected using Py.SO 3 complex in H 2 O to provide 8-, 10-and 12-mer heparin-like oligosaccharides 26-28. Figure 3 . MALDI MS of dodecasaccharide 19 (MNa + shown). 45 Protected and partially/fully-deprotected oligosaccharides of this nature present analytical challenges. In this series, high field NMR (800MHz) of the fully protected octa-, deca-and dodecasaccharides (15, 17, and 19) , provided assignment of the diagnostic anomeric signals and constituent disaccharide 50 repeating units, whilst MS analysis using MALDI techniques, proved very reliable (see Figure 3 for analysis of dodecamer 19) .
Optimum analysis of oligosaccharides 23-28 required negative mode ESI-MS on samples that had undergone a carboxylic and sulfonic acid counter-ion salt switch (from Na + to NH 4 + ) prior to 55 analysis. This produced significantly less complicated spectra compared to those seen with the common Na + counterion. 11 Characterization of final oligosaccharide length and homogeneity was supported by 800MHz NMR analyses and PAGE analysis for synthetic compounds 26-28 (Figure 4) , 60 compared to heparin digest oligosaccharides of known length (Iduron). Thus, PAGE runs comparing octa-, deca-and dodecasaccharides from biological digests with synthetic 26-28 and showed good correlations. 65 
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heparin digests synthetic oligosaccharides Figure 4 . Azure A stained PAGE analysis of 26 (8-mer) , 27 (10-mer) and 28 (12-mer) vs heparin digest 8-, 10-and 12-mer comparisons (4 μg loading). † 70 We previously reported that FGF2-and VEGF 165 -mediated signalling pathways and endothelial cell functions are inhibited by a series of lower-sulphated synthetic (S0I2) n (n≤6) HS oligosaccharides. 2a The most potent inhibition was achieved with longer oligosaccharide sequences and N-sulfation of glucosamine 75 residues was essential for activity.
We thus used FGF2-and VEGF 165 -dependent endothelial cell proliferation and migration in vitro assays to evaluate whether introducing per-6-O-sulfation into (SI) n sequences altered the potential to inhibit FGF2-and VEGF 165 -dependent endothelial 80 cell functions. (Fig. 5 and 6) .
The proliferation results show that oligosaccharides 26 and 27 inhibit FGF2, whilst dodecasaccharide 28 supports the activity of FGF2 (Fig. 5) ; findings that are in keeping with our previous in vivo study of size-fractionated 6-O-sulfated heparin 85 oligosaccharides. 2j Moreover, this contrasts dramatically with the effect of our previously-reported synthetic [GlcNS-IdoA2S] 6 -OMe dodecasaccharide, where FGF2-mediated cell proliferation was inhibited by 85%. Access to the new synthetic 6-O-sulfated dodecasaccharide 28 thus enables proof of a key structure-90 function switch in which 28 supports FGF-mediated proliferation, whilst its direct 6-O-desulfated synthetic analogue is very substantively inhibitory. Oligosaccharides 26-28 affect FGF2-and VEGF165-induced human umbilical vein endothelial cell (HUVEC) proliferation. HUVECs were maintained in endothelial cell growth media without supplements 5 containing 1% fetal bovine serum (FBS) for six hours before adding FGF2 and VEGF165 at 5 ng/ml and 2.5 ng/ml concentration, respectively. HUVECs were cultured with the growth factors in the presence or absence of oligosaccharides (50 μg/ml) for 96 hours. Cell proliferation was evaluated using sulforhodamine B assay. FGF2-and VEGF165-10 induced HUVEC proliferation in the absence of oligosaccharides is expressed as 100%. Results are shown as mean ± SEM.
All three oligosaccharides 26-28 inhibited FGF2-mediated endothelial cell migration by 45-70 % ( Figure 6 ). However, our 15 previously-reported synthetic [GlcNS-IdoA2S] 6 -OMe dodecasaccharide completely inhibited FGF2-mediated cell migration. This also provides another significant advancement in proof of the very different effects of sulfation within such synthetic oligosaccharides. 20 In VEGF 165 -mediated cell proliferation and migration assays ( Figures 5 and 6 ) the activities of the 8-mer (26) and 12-mer (28) were almost identical whereas the 10-mer (27), whilst having little effect on proliferation (Fig 2a) , was significantly more effective, inhibiting cell migration by 70%. Notably, this is 25 comparable in effect to the inhibition of VEGF-mediated migration by our synthetic 6-O-desulfated [GlcNS-IdoA2S] 6 -OMe dodecasaccharide. 2a This provides an interesting contrast between the relationship of oligosaccharide length and sulfation levels in inhibiting VEGF-mediated processes. 30 Overall, these results, when compared with our prior biological inhibition data for the lesser-sulphated synthetic analogue series, indicate that the number and specific positions of sulphate residues in HS-related oligosaccharides have a significant role in affecting different FGF2-and VEGF 165 - HUVECs were seeded to form confluent monolayers that were maintained in endothelial cell growth media without supplements 50 containing 2% FBS for 24 hours. Following serum-starvation monolayers were wounded and FGF2 or VEGF165 with or without oligosaccharides (50 μg/ml) were added at 5 ng/ml and 2.5 ng/ml concentration, respectively, for 24 hours. The images of unpopulated areas were analysed using MetaMorph image analysis software by measuring 55 unpopulated area at 0 and 24 hours. Cell advancement area was derived for each treatment. The control treatment with FGF2 or VEGF165 alone is presented as 100%. Results are expressed as mean ± SEM
Conclusions
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In summary we have demonstrated an efficient 2+(2) n iduronate donor-disaccharide-based synthesis of heparin-like oligosaccharides, delivering the first examples of deca-and dodecasaccharides with the (SI) repeat unit. The protected octasaccharide precursor can be prepared on up to multi-hundred- 65 mg scales and demonstrates a robust entry to access essential, structurally-defined [GlcNS6S-IdoA2S] n oligosaccharides. Evaluation of these compounds in in vitro endothelial cell-based assays has enabled us to highlight the critical role that the glucosamine-6-O-sulphate residue plays in the regulation of
